DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health
  • National Cancer Institute (/ NCI R50CA243878)
  • National Cancer Institute (P30 CA014089)
  • National Cancer Institute (R35 CA209859)